ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.
Hosted on MSN
IBRX stock sees volatile session – ImmunityBio’s update in phase 2 glioblastoma trial sparks buzz
・The company added that patients in this trial represent a “particularly challenging” population. ・The Culver City, California-based immunotherapy company stated that as of Jan. 22, 2026, it had ...
Hosted on MSN
Why ImmunityBio stock is skyrocketing again today
ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials. It also highlighted initial success in treating patients with Non-Hodgkin lymphoma ...
Zacks.com on MSN
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last?
ImmunityBio (IBRX) shares soared 41.9% in the last trading session to close at $8.54. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...
Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) with or ...
Financial giants have made a conspicuous bullish move on ImmunityBio. Our analysis of options history for ImmunityBio (NASDAQ:IBRX) revealed 19 unusual trades. Delving into the details, we found 57% ...
ImmunityBio, Inc. (NASDAQ:IBRX) is among the best NASDAQ stocks under $10 to buy. On December 15, Edward Tenthoff, an analyst at Piper Sandler, maintained a ‘Buy’ rating on ImmunityBio, Inc.
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code ...
On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication. ImmunityBio's fantastic week continued on Thursday, after ...
Pharmaceutical drugs developed by two local companies received approvals in the European Union last month. On Dec. 12, Culver City-based ImmunityBio Inc. announced that the European Medicines Agency, ...
Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results